“…Diabetes is a chronic disease where the body is unable to regulate blood glucose level within the normal range. , Traditional administrations of exogenous insulin via subcutaneous injection and noninvasive therapy such as oral, nasal, transdermal, and ocular delivery systems cannot regulate insulin release continuously and automatically in response to the blood glucose fluctuation because the glucose-sensing and insulin-releasing modules are not directly integrated. , To resolve these issues for diabetic patients and reduce the incidence of hyperglycemia and hypoglycemia, smart therapies called closed-loop insulin release, which can precisely control the insulin amount on demand, have been broadly developed. − Among them, phenylboronic acid (PBA)-based glucose-triggered systems have attracted great interest because PBA and its derivatives can conjugate with glucose molecules to form a reversible ester bond for the achievement of the closed-loop effect. , Until now, a variety of PBA-based glucose-responsive materials, especially in the form of nanoparticles including nanogels (microgels), , micelles, − vesicles, − and nanocapsules, , have been broadly explored to improve their glucose concentration sensitivity and on–off regulated response in a physiological environment. Most of the PBA-based nanocarriers in the reported examples rely on the versatile architectural design of the glucose-responsive materials themselves to modulate the sensitivity of insulin release in response to blood glucose level changes. − The coassembly of amphiphilic copolymers is one highly efficient and convenient method to obtain nanoparticles with the special properties of the individual copolymers . Inspired by the higher ordered structures of synthetic polypeptides, we are curious whether simple changes in the secondary conformation of the nanocarriers via the coassembly of PBA-based polymers and amphiphilic polymers with polypeptide blocks will generate a great impact on the self-regulated response of the overall materials.…”